Ann: Massachusetts General Hospital for US Clinical Study Site-RAP.AX, page-84

I agree,

ResApp don't need to grovel. There is no other competition that can allow Telehealth companies to circumnavigate their #1 big problem:

They are currently unable to 'teleport their stethoscope through the screen'.

ResApp are in a position where they will be sought out by international clients, some post FDA approval, others (IMO) will seek agreements pre FDA that will come into effect pending FDA approval.

Other countries may even be content to allow the use of the app pre FDA. It depends on the country and their regulatory requirements. Since this is marketed as a diagnostic tool, the final diagnosis hangs on the tele-doctor, not on ResApp. Of course doctors feel more comfortable hanging their hat on a diagnosis tool that comes with FDA approval and the big thing for us is that RAP can charge accordingly.

ResApp just need to have a clear game plan for each type of client and country as they receive offers of engagement from potential clients. We don't want to see months of 'um and ahing' before customers agreements convert to revenue.

ResApp will do well to ensure they are pre-equiped with the knowledge and pathway to commercialisation for each country/regional area.. ie tax/foreign investment laws, processes for money transfers back to Aust etc, so that these structures can be put into place ahead of commercialisation.

That will ensure there is no delay/bottleneck in potential inflows of revenue.

Given the productiveness of management so far, I think people here can rest assured that the aforementioned is also receiving their attention.

Regards,

CT